In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1+ BCP-ALL

Eleanor R. C. Fiedler, Arjun Bhutkar, Emily C. Lawler, Rana H. Besada, Michael T. Hemann

Blood Advances · 2018 · 15 citations · 30 references

DOIFull text

Open access

Concepts

Abstract

Key Points Functional in vivo screening reveals distinct genetic dependencies in a mouse model of BCR-ABL1+ BCP-ALL after dasatinib treatment. Disruption of the PAF/PAFR/PAFAH1B axis sensitizes leukemia cells to TKIs; this pathway may be a novel target for combination therapy.

References

30